LYRA: Lyra Therapeutics Inc Company Profile & Statistics

About

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and consistently deliver medicines directly to the affected tissue. Its initial product candidates consist LYR-210 and LYR-220 which are in clinical stage. Lyra Therapeutics Inc. is based in Watertown, Mass.

Info & Links

CEO

Maria Palasis

Headquarters

480 ARSENAL STREET
WATERTOWN, MA 02472, UNITED STATES

Auditor

BDO USA, P.C.

Share holders

Employees

Lyra Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

11.24M

Enterprise Value

-12.56M

Enterprise Value/EBITDA(ttm)

0.12

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

8.13

Price to Book(mrq)

0.58

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-4644.87%

Profit Margin(ttm)

-7184.63%

Return on Equity(ttm)

-125.07%

Return on Invested Capital(ttm)

-258.88%

Return on Assets(ttm)

-59.74%

Income Statement

Revenue(ttm)

1.47M

Revenue Per Share(ttm)

0.02

Gross Profit(ttm)

1.47M

EBITDA(ttm)³

-104.11M

Net Income Available to Common(ttm)

-97.61M

Diluted EPS(ttm)

-1.49

Share Statistics

Beta (5Y Monthly)

-0.12

52-Week Change

-95.15%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

65.46M

Dividend Yield

0.00%

Float⁴

62.39M

% Held by Insiders

4.69%

% Held by Institutions

95.62%

Balance Sheet

Total Cash(mrq)

51.63M

Total Cash Per Share(mrq)

0.79

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.64%

Quick Ratio(mrq)

3.64%

Book Value Per Share(mrq)

0.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.90

Free Cash Flow(ytd)

-61.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LYRA

Lyra Therapeutics Inc

Lyra Therapeutics Inc Profile